loader2
Login Open ICICI 3-in-1 Account

Shree Ganesh Remedies Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Shree Ganesh Remedies Ltd. 06 Feb 2025 12:29 PM

Q3FY25 Quarterly Result Announced for Shree Ganesh Remedies Ltd.

Pharmaceuticals company Shree Ganesh Remedies announced Q3FY25 results

  • Revenue from Operations: Rs 27.05 crore compared to Rs 27.97 crore during Q3FY24, change -3%.
  • EBITDA: Rs 9.90 crore compared to Rs 8.21 crore during Q3FY24, change 21%.
  • EBITDA margin: 36.6% for Q3FY25.
  • PBT: Rs 7.54 crore compared to Rs 7.42 crore during Q3FY24, change 2%.
  • PAT: Rs 5.43 crore compared to Rs 4.82 crore during Q3FY24, change 13%.
  • EPS: Rs 4.23 for Q3FY25.

Gunjan Kothia, Promoter, Whole-Time Director, said: I am pleased to share our performance update for Q3FY25. In this quarter, we experienced a decline in revenue due to intensified domestic competition for our traditional products, which led to price reductions and impacted profitability. However, it is noteworthy that we achieved robust growth in volumes during this period. The decline in profitability from traditional products was effectively offset by the high margins generated from our CRAMS projects, as previously guided.

On the operational front, the ramp-up of Block 8 is progressing according to plan, and we anticipate reaching optimal capacity utilisation by early next financial year. Leveraging this steady ramp-up, we have decided to undertake a maintenance and refurbishment shutdown of Block 3 during the current quarter. While this shutdown means we do not foresee volumetric growth for this quarter, we are wellpositioned to manage the volume decline from Block 3 with the increased output from Block 8.

Furthermore, I am pleased to announce that the designing phase of Block 7 has been completed, and construction activities have commenced. We expect to complete this new block by the end of Q4FY26 and initiate commercial production in Q1FY27. Additionally, recognising the strong opportunities ahead, we are intensifying our R&D efforts by adding an R&D block at our existing site. The design work is currently underway, and construction will begin shortly.

A significant highlight of this quarter is our recent Memorandum of Understanding (MOU) with a leading Japanese company. This Long-Term Strategic Supply Agreement marks a pivotal step in our strategic contract manufacturing venture within the specialty chemicals market. Under this agreement, we will manufacture three innovative products that will be introduced as the first of their kind in India. This partnership not only showcases our capabilities but also positions us to meet growing international market demands effectively.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app